Applovin Corporation R&D increased by 14.5% to $94.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 66.8%, from $56.41M to $94.10M. Over 3 years (FY 2021 to FY 2025), R&D shows a downward trend with a -14.8% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $77.46M | $108.52M | $119.54M | $126.25M | $141.11M | $122.06M | $118.19M | $144.85M | $137.42M | $159.29M | $155.32M | $99.12M | $80.78M | $105.86M | $56.41M | $44.03M | $43.85M | $82.22M | $94.10M |
| QoQ Change | — | +40.1% | +10.2% | +5.6% | +11.8% | -13.5% | -3.2% | +22.6% | -5.1% | +15.9% | -2.5% | -36.2% | -18.5% | +31.1% | -46.7% | -21.9% | -0.4% | +87.5% | +14.5% |
| YoY Change | — | — | — | — | +82.2% | +12.5% | -1.1% | +14.7% | -2.6% | +30.5% | +7.2% | -27.9% | -49.3% | — | -63.7% | -55.6% | -45.7% | -22.3% | +66.8% |